Benzinga

Benzinga

Benzinga

lunes, agosto 24

Arcturus Therapeutics Holdings Inc

ARCTNASDAQ
Trade with Public
Trade with Public
$13.45
2.4622.38%
al cierre: Aug 20, 5:00 PM EST
$13.18
2.1919.93%
Premercado: 8:09 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Arcturus Therapeutics Financials

Arcturus Therapeutics (ARCT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Arcturus Therapeutics Q2 EPS $(0.84) Beats $(1.00) Estimate, Sales $2.959M Miss $3.199M Estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.00) by 16 percent. This is a 147.06 percent decrease over losses of $(0.34) per share
Benzinga Newsdesk

PRO
Arcturus Therapeutics Q1 EPS $(0.95) Beats $(1.00) Estimate, Sales $2.061M Miss $7.233M Estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.00) by 5 percent. This is a 82.69 percent decrease over losses of $(0.52) per share from
Benzinga Newsdesk

Arcturus Therapeutics Q4 Earnings Assessment

Benzinga Insights

PRO
Arcturus Therapeutics Q4 EPS $(1.03) Misses $(0.98) Estimate, Sales $7.196M Miss $17.669M Estimate

Benzinga Newsdesk

Earnings Scheduled For March 3, 2026

Benzinga Insights

Earnings Preview: Arcturus Therapeutics

Benzinga Insights

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved